{
    "clinical_study": {
        "@rank": "48704", 
        "arm_group": {
            "arm_group_label": "Icotinib", 
            "arm_group_type": "Experimental", 
            "description": "Patients receive icotinib 125 mg three times daily as adjuvant chemotherapy with for 18 months after surgery."
        }, 
        "brief_summary": {
            "textblock": "Adjuvant therapy has been proved effective in treating earlier stage or less advanced\n      non-small-cell lung cancer. This study is designed to evaluate the efficacy of icotinib as\n      adjuvant therapy in treating stage IIA-IIIA adenocarcinoma patients with EGFR mutation. The\n      primary endpoint is disease-free survival."
        }, 
        "brief_title": "Icotinib as an Adjuvant Therapy for Patients With Stage IIA-IIIA (N0-1) Adenocarcinoma With EGFR Mutation", 
        "completion_date": {
            "#text": "July 2017", 
            "@type": "Anticipated"
        }, 
        "condition": "Non-small Cell Lung Cancer", 
        "condition_browse": {
            "mesh_term": [
                "Adenocarcinoma", 
                "Carcinoma, Non-Small-Cell Lung", 
                "Lung Neoplasms"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  The patients present with operable stage IIA-IIIA (N0-1) lung adenocarcinoma with 19\n             or 21 exon mutation\n\n          -  The patients have no history of anti-cancer therapies including chemotherapy,\n             radiation therapy\n\n          -  The patients' Eastern Cooperative Oncology Group scores are \u2264 0-1\n\n          -  The patients signed the written informed consent\n\n        Exclusion Criteria:\n\n          -  Patients with unresected tumor\n\n          -  Wild EGFR type\n\n          -  Allergic to the study drug\n\n          -  Patients have severe non-cancerous diseases\n\n          -  Patients are undergoing current administration of anti-cancer therapies, or are\n             attending some other clinical trials"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "75 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "80", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "January 21, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02044328", 
            "org_study_id": "BD-IC-IV57"
        }, 
        "intervention": {
            "arm_group_label": "Icotinib", 
            "description": "Icotinib is administered 125 mg three times per day.", 
            "intervention_name": "Icotinib", 
            "intervention_type": "Drug", 
            "other_name": [
                "Commana", 
                "BPI-2009"
            ]
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "February 18, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Beijing", 
                    "country": "China", 
                    "state": "Beijing", 
                    "zip": "100053"
                }, 
                "name": "Xuanwu Hospital, Capital Medical University"
            }
        }, 
        "location_countries": {
            "country": "China"
        }, 
        "number_of_arms": "1", 
        "official_title": "Icotinib as an Adjuvant Therapy for Patients With Stage IIA-IIIA (N0-1) Adenocarcinoma With EGFR Mutation: a Prospective, Exploratory Study", 
        "other_outcome": {
            "description": "Compare the disease-free survival between patients with positive Bcl-2 interacting mediator of cell death mutation and patients without this mutation.", 
            "measure": "Difference of disease-free survival by status of Bcl-2 interacting mediator of cell death", 
            "safety_issue": "No", 
            "time_frame": "2 years"
        }, 
        "overall_official": {
            "affiliation": "Xuanwu hospital capital medical university", 
            "last_name": "Zhang Yi, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Active, not recruiting", 
        "oversight_info": {
            "authority": "China: Food and Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "June 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Disease-free survival", 
            "safety_issue": "No", 
            "time_frame": "2 years"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02044328"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "1-year Survival Rates", 
                "safety_issue": "No", 
                "time_frame": "1 year"
            }, 
            {
                "measure": "3-year Survival Rates", 
                "safety_issue": "No", 
                "time_frame": "3 years"
            }, 
            {
                "description": "Adverse events are evaluated and coded by Common Terminology Criteria for Adverse Events version 4.0", 
                "measure": "Number of patients suffered adverse events", 
                "safety_issue": "Yes", 
                "time_frame": "42 months"
            }
        ], 
        "source": "Betta Pharmaceuticals Co.,Ltd.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Betta Pharmaceuticals Co.,Ltd.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "January 2014", 
        "study_design": "Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "February 2014"
    }
}